1. Scrip
  2. >>Business
  3. >>Deals

Arcturus Enters Reverse-Merger With Alcobra To Push Differentiated RNA Approach

 
• By Joseph Haas

One company’s disappointment is another’s opportunity, as Arcturus will go public by merging with troubled Alcobra. The combined company will have seven preclinical programs, four run by partners.

Handshake of businessmen

Arcturus Therapeutics Inc. will get a public structure and added cash to make good on its ambitions to improve on other RNA therapeutics companies’ offerings as it enters a reverse-merger with troubled Israeli biotech Alcobra Ltd.

The all-stock transaction announced on Sept. 28, which has been approved by both companies’ boards of directors but still needs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Pfizer Jumps Back Into Obesity With $4.9bn Bid For Metsera

 
• By Joseph Haas

Months after terminating obesity candidate danuglipron, Pfizer is placing a hefty bet on Metsera and what it calls its highly differentiated incretin/amylin analog candidates.

Deal Watch: Biogen Acquires Intrathecal Delivery Specialist Alcyone

 
• By Joseph Haas

Plus deals involving Frame Bio/Mercury Bio, Arch Biopartners/Lidpro, Lilly/Remedium, Cadrenal/eXIthera, Vertex/Enlaza and more.

Nanobiotix/J&J Early Melanoma Data Show Potential For Future Indication

 
• By Mandy Jackson

Radiotherapy enhancer JNJ-1900 (NBTXR3) generated a 47% ORR and 78.9% DCR in melanoma patients after multiple prior rounds of treatment. Discussions about development in additional cancers are ongoing with partner J&J.

Roche Makes Major MASH Bid, Offering $2.4bn For 89bio

 
• By Joseph Haas

About four months after GSK paid $1.2bn up front for another FGF21 analog in MASH, Roche looks to buy 89bio, adding Phase III pegozafermin to its growing cardiometabolic pipeline.

More from Business

Why India Revoked The Entresto Patent And Novartis Abstained From Proceedings

 
• By Anju Ghangurde

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: GSK announces US investments during Trump’s UK visit; Lilly thinks twice about UK lab investment; analyzing the rise in China R&D and deals; Regeneron CEO on his company’s ignored blockbusters; and AstraZeneca’s COPD trial failure.

Deal Watch: Biogen Acquires Intrathecal Delivery Specialist Alcyone

 
• By Joseph Haas

Plus deals involving Frame Bio/Mercury Bio, Arch Biopartners/Lidpro, Lilly/Remedium, Cadrenal/eXIthera, Vertex/Enlaza and more.